Cover Image
市場調查報告書

RemiFentanyl的中國市場

Investigation Report on China Remifentanil Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 338986
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
RemiFentanyl的中國市場 Investigation Report on China Remifentanil Market, 2009-2018
出版日期: 2015年09月07日 內容資訊: 英文 20 Pages
簡介

RemiFentanyl (鹽酸RemiFentanyl) 是新世代的鎮靜劑,由於短時間的作用表現和控制性高而成為理想的靜脈麻醉劑。中國國內的調查對象醫院,RemiFentanyl的銷售額 (2014年)為 2億人民幣,2005∼2014年的年複合成長率(CAGR) 成為30%以上。隨著人口高齡化,及環境污染、生活習慣的變化伴隨的疾病增加,中國國內的手術數量增加,預期RemiFentanyl的需求也將擴大。

本報告提供中國的RemiFentanyl的市場相關分析、RemiFentanyl的特徵和認證情形、市場整體規模、各企業/各劑型的市場佔有率、價格趨勢、主要製造商簡介、今後的市場成長預測等調查評估。

第1章 RemiFentanyl的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的RemiFentanyl市場簡介

  • 中國國內的RemiFentanyl的專利申請、核準情況
  • 主要製造商
  • 市場規模

第3章 中國國內的RemiFentanyl銷售額分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 RemiFentanyl的主要廠商的市場佔有率 (過去5年份)

  • 市場佔有率 (以金額為準)
  • 市場佔有率 (以數量為準)

第5章 中國國內的RemiFentanyl的劑型 (過去5年份)

  • 各劑型的市場佔有率 (以金額為準)
  • 各劑型的市場佔有率 (以數量為準)

第6章 中國的醫院的RemiFentanyl的參照價格

  • Wuhan Humanwell Pharmaceutical Co., Ltd
  • China National Pharmaceutical Industry Corporation Ltd

第7章 中國國內的RemiFentanyl的主要製造商 (過去5年份)

  • Wuhan Humanwell Pharmaceutical Co., Ltd
  • China National Pharmaceutical Industry Corporation Ltd

第8章 中國國內的RemiFentanyl市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境的預測

圖表一覽

目錄
Product Code: 1509315

As a new generation of opiates, remifentanil (remifentanil hydrochloride) is an ideal intravenous anesthetic with short onset and good controllability. Remifentanil hydrochloride injection is a narcotic used for the maintenance of general anesthesia.

In China, there is still a large space for narcotic market to grow. And fentanyl takes up over 50% i.e. CNY 5 billion of the narcotic market. As remifentanil is addictive, its production and sales is strictly controlled by the Chinese government who regulates that the number of API manufacturers shall not exceed two while the number of prepration makers shall also be limited. Hence the high barrier. The current landscape of Wuhan Humanwell Pharmaceutical Co., Ltd taking the lead might be changed with the entry of China National Medicines Corporation Limited and Jiangsu Nhwa Pharmaceutical Co., Ltd.

According to CRI's market survey, the sales value of remifentanil in sample hospitals exceeded CNY 200 million in 2014 and CAGR during the period of 2005-2014 surpassed 30%. Currently, remifentanil products available in the Chinese market all come from Wuhan Humanwell Pharmaceutical Co., Ltd and China National Pharmaceutical Industry Corporation Ltd, among which the former had the largest market share of over 99% for sales value in 2014.

With ageing population and increasing incidence of various diseases caused by environmental pollution and lifestyle changes, the number of operation in China will keep rising, so does the demand for remifentanil.

Readers can get at least the following information through this report:

  • market size of remifentanil in China
  • competitive landscape of remifentanil market in China
  • price of remifentanil made by different enterprises in China
  • market outlook of remifentanil in China

The author suggests the following groups of people purchase this report:

  • Pharmaceutical Manufacturers
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Remifentanil

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Remifentanil in China

  • 2.1. Patent and Approval Information of Remifentanil in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Remifentanil Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Remifentanil Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Remifentanil in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Remifentanil in Chinese Hospitals in 2014

  • 6.1. Wuhan Humanwell Pharmaceutical Co., Ltd
  • 6.2. China National Pharmaceutical Industry Corporation Ltd

7. Major Manufacturers of Remifentanil in Chinese Market, 2010-2014

  • 7.1. Wuhan Humanwell Pharmaceutical Co., Ltd
  • 7.2. China National Pharmaceutical Industry Corporation Ltd

8. Market Outlook of Remifentanil in China, 2015-2019

8.1Forecast of Market Size

  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Remifentanil in China
  • Chart Remifentanil Sales in China
  • Chart Sales Value of Remifentanil in China, 2010-2014
  • Chart Sales Value of Remifentanil in Some Regions in China, 2010-2014
  • Chart Sales Volume of Remifentanil in China, 2010-2014
  • Chart Sales Volume of Remifentanil in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Remifentanil Made by Wuhan Humanwell in China, 2010-2014
  • Chart Sales Value and Market Share of Remifentanil Made by China National Pharmaceutical Industry Corporation Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Remifentanil Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Remifentanil Injection in China, 2010-2014
  • Chart Price of Remifentanil Made by Wuhan Humanwell in Some Chinese Cities in 2014
  • Chart Price of Remifentanil Made by China National Pharmaceutical Industry Corporation Ltd in Some Chinese Cities in 2014
Back to Top